Chronic Cough
- Cough hypersensitivity and chronic cough
- The current and emerging treatment landscape for chronic cough
- Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials
- Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups
- Healthcare utilization and costs in chronic cough
- Incidence and Prevalence of Cough in a Rural Health System: A 20-Year Study
- Chronic cough: new insights and future prospects
- On Chronic Cough Diagnosis, Classification, and Treatment
- Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant
- Understanding the Foundations of Chronic Cough
- American Lung Association: Chronic Cough Resources and Videos
- European Respiratory Society Guidelines on the Diagnosis and Treatment of Chronic Cough in Adults and Children
- Management of chronic refractory cough in adults
- Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial
- P2X3-Receptor Antagonists as Potential Antitussives: Summary of Current Clinical Trials in Chronic Cough
Pain Management
Peyronie’s Disease
- A clinical pathway for the management of Peyronie’s disease: integrating clinical guidelines from the International Society of Sexual Medicine, American Urological Association and European Urological Association
- JAMA Patient Page: Peyronie’s Disease
- Peyronie’s Disease
- Peyronie’s disease: new paradigm for the treatment of a unique cause of erectile dysfunction
Substance Use Disorders
- NIH/National Institute on Drug Abuse – Patient Information
- Sublocade Prescribing Information
- Medication Assisted Treatment (MAT) Certification
- Substance Abuse & Mental Health Services Administration (SAMHSA) supported CME courses on prescribing opioids for chronic pain from AAAP, AOAAM, ASPMNDPT, ATTC and ASAM
